Reference : Pharma-clinics. Le medicament du mois. L'alendronate (Fosamax).
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Pharma-clinics. Le medicament du mois. L'alendronate (Fosamax).
[en] Drug clinics. The drug of the month. Alendronate (Fosamax)
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale de Liège
CHU de Liège
Yes (verified by ORBi)
[en] Absorption ; Alendronate/pharmacokinetics/pharmacology/therapeutic use ; Biological Availability ; Bone Density ; Bone and Bones/drug effects ; Fasting ; Female ; Fractures, Bone/prevention & control ; Humans ; Osteoclasts/drug effects ; Osteoporosis, Postmenopausal/drug therapy ; Randomized Controlled Trials as Topic ; Spinal Fractures/prevention & control
[en] Alendronate (Fosamax, Merck Sharp & Dohme) is an aminobisphosphonate which inhibits bone turnover by suppressing the activity of osteoclasts without increasing the risk of osteomalacia. Alendronate is highly effective at preventing bone loss associated to absence of endogenous estrogen and induces a sustained increase in bone mass. Fosamax is indicated and reimbursed in the treatment of osteoporosis in postmenopausal women, with either an history of bone fracture confirmed by X-ray exam or obvious osteoporosis assessed by bone mineral density measurement. The recommended dosage is 10 mg once daily, continuously. The drug should be absorbed after an overnight fast to improve its bioavailability and with a big glass of plain water to reduce the risk of oesophageal ulcerations. Large randomized controlled trials for up to 3 years have demonstrated that alendronate is able to reduce the risk and rate of occurrence of vertebral and nonvertebral fractures in postmenopausal women.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.